Core Viewpoint - The announcement from Aojing Medical indicates that shareholder Qilun Tianyou has reduced its stake in the company through a centralized bidding process, which is part of a previously disclosed reduction plan and does not affect the company's governance structure or ongoing operations [1] Summary by Relevant Sections - **Shareholder Activity** - Qilun Tianyou reduced its holdings by 300,000 shares, representing 0.22% of the total share capital of Aojing Medical [1] - The shareholding percentage decreased from 6.18% to 5.96%, with the change reaching a 1% threshold [1] - **Reduction Plan** - The reduction is in line with the previously disclosed plan and is classified as a normal reduction [1] - As of the announcement date, the reduction plan has not been fully implemented [1]

截至2025年12月24日收盘，奥精医疗(688613)报收于21.25元，上涨0.76%，换手率2.52%，成交量3.46万 手，成交额7331.73万元。 奥精医疗：关于审计机构变更项目质量控制复核人的公告 奥精医疗科技股份有限公司于2025年12月24日发布公告，因立信会计师事务所内部工作调整，将公司 2025年度审计项目质量控制复核人由单大信变更为王芳。王芳为中国注册会计师，自2012年起在立信执 业，2025年开始为公司提供审计服务，近三年未因执业行为受过处罚，符合独立性要求。本次变更不影 响审计工作安排，不会对公司2025年度审计产生不利影响。 当日关注点 交易信息汇总资金流向 12月24日主力资金净流入225.4万元；游资资金净流入94.84万元；散户资金净流出320.24万元。 公司公告汇总 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：12月24日主力资金净流入225.4万元，散户资金呈净流出态势。 来自公司公告汇总：奥精医疗变更2025年度审计项目质量控制复核人，由单大信变更为王芳，系 因立信 ...

截至2025年12月23日收盘，奥精医疗(688613)报收于21.09元，下跌4.31%，换手率4.04%，成交量5.53万 手，成交额1.18亿元。 奥精医疗：关于审计机构变更项目质量控制复核人的公告 奥精医疗科技股份有限公司于2025年12月24日发布公告，因立信会计师事务所内部工作调整，将公司 2025年度审计项目质量控制复核人由单大信变更为王芳。王芳为中国注册会计师，自2012年起在立信执 业，2025年开始为公司提供审计服务，近三年未因执业行为受过处罚，符合独立性要求。本次变更不影 响审计工作安排，不会对公司2025年度审计产生不利影响。 当日关注点 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 交易信息汇总 来源【交易信息汇总】：12月23日主力资金净流出488.4万元，显示主力短期谨慎态度。 来源【公司公告汇总】：奥精医疗变更2025年度审计项目质量控制复核人，由单大信变更为王 芳，系事务所内部调整所致。 资金流向 12月23日主力资金净流出488.4万元；游资资金净流入632.39万元；散户资金净流出143.99 ...

Core Viewpoint - Aojing Medical announced the appointment of Wang Fang as the quality control reviewer for the 2025 audit project, replacing Shan Daxin due to internal adjustments at the auditing firm [2] Group 1 - Aojing Medical has appointed Lixin Accounting Firm as the auditing institution for the fiscal year 2025 [2] - The original quality control reviewer, Shan Daxin, has been replaced by Wang Fang due to internal work adjustments at Lixin Accounting Firm [2]

Group 1 - The medical device sector experienced a decline of 0.89% compared to the previous trading day, with AoJing Medical leading the drop [1] - On the same day, the Shanghai Composite Index closed at 3919.98, up 0.07%, while the Shenzhen Component Index closed at 13368.99, up 0.27% [1] - A detailed table of individual stock performance within the medical device sector is provided [1] Group 2 - The net outflow of main funds in the medical device sector was 628 million yuan, while retail funds saw a net inflow of 439 million yuan [2] - The net inflow of speculative funds amounted to 189 million yuan [2] - A detailed table of fund flows for individual stocks in the medical device sector is included [2]

奥精医疗科技股份有限公司（以下简称"公司")于2025年4月25日召开第二届 董事会第十三次会议，于2025年5月16日召开2024年年度股东大会，审议通过了《关 于续聘公司2025年度审计机构的议案》，同意公司续聘立信会计师事务所（特殊普 通合伙）作为公司2025年度财务报告及内部控制审计机构。具体内容详见公司于 2025年4月26日刊登于上海证券交易所网站（www.sse.com.cn）的《关于续聘会计师 事务所的公告》（公告编号：2025-011）。 公司于近日收到立信会计师事务所通知，立信会计师事务所因内部工作调整， 变更了项目质量控制复核人。现将具体情况公告如下： 一、 本次项目质量控制复核人变更情况 立信会计师事务所作为公司2025年度审计机构，原指派单大信作为质量控制复 核人，鉴于内部工作调整，立信会计师事务所指派王芳接替单大信作为公司2025年 审计项目的质量控制复核人。 二、 本次变更项目质量控制复核人员的基本信息、诚信记录和独立性情况 证券代码：688613 证券简称：奥精医疗 公告编号：2025-066 奥精医疗科技股份有限公司 关于审计机构变更项目质量控制复核人的公告 本公司董事会及全 ...

Group 1 - The core transaction on December 17 involved a block trade of 150,000 shares of Aojing Medical, with a transaction value of 2.8887 million yuan, at a price of 19.26 yuan per share, reflecting a discount of 1.98% compared to the closing price [1][2] - Over the past three months, Aojing Medical has recorded a total of five block trades, amounting to a cumulative transaction value of 12.8265 million yuan [1] - The closing price of Aojing Medical on the day of the transaction was 19.65 yuan, showing a decline of 1.16%, with a daily turnover rate of 3.28% and a total trading volume of 87.052 million yuan [1][2] Group 2 - The latest margin financing balance for Aojing Medical is 165 million yuan, with an increase of 1.261 million yuan over the past five days, representing a growth rate of 0.77% [2] - Aojing Medical Technology Co., Ltd. was established on December 22, 2004, with a registered capital of 1.37008584 billion yuan [2]

Core Insights - A total of 19 stocks on the Sci-Tech Innovation Board (STAR Market) experienced block trading on December 17, with a cumulative transaction value of 401 million yuan [1][2]. Trading Overview - The highest transaction value was recorded for Tuojing Technology, with 2 block trades totaling 300,000 shares and a transaction amount of 100 million yuan. Other notable transactions included Huahai Qingshi and Xinghuan Technology, with transaction amounts of 63.68 million yuan and 48.36 million yuan respectively [1][2]. - The average discount rate for block trades relative to the closing price was highest for Kangxi Communication, Aisen Co., and Anbotong, with discount rates of 19.93%, 18.61%, and 15.00% respectively. The only stock with a premium was Haosen Intelligent, with a premium rate of 0.57% [1][2]. Market Performance - The STAR 50 Index rose by 2.47% on the same day, with 459 stocks (76.88%) on the STAR Market experiencing price increases. The average increase for stocks involved in block trading was 0.85%, with the largest gains seen in Xinghuan Technology, Dekeli, and Lankai Technology, which rose by 5.71%, 4.28%, and 3.28% respectively. Conversely, Guobo Electronics, Aisen Co., and Ao Precision Medical saw declines of 2.45%, 1.68%, and 1.16% respectively [1][2]. Institutional Participation - Among the block trades, 12 transactions involved institutional buyers or sellers, covering 8 stocks. The leading stocks for institutional purchases were Tuojing Technology, Xinghuan Technology, and Aojie Technology, with purchase amounts of 100 million yuan, 48.36 million yuan, and 39.77 million yuan respectively. The primary stock sold by institutions was Guobo Electronics, with a selling amount of 5.02 million yuan [2][3]. Fund Flow Analysis - Of the stocks involved in block trading, 6 experienced net inflows of funds, with the highest net inflows recorded for Lankai Technology, Dekeli, and Xinghuan Technology, amounting to 116 million yuan, 91.76 million yuan, and 48.10 million yuan respectively. In contrast, Tuojing Technology, Huahai Qingshi, and Aisen Co. faced net outflows of 142 million yuan, 70.34 million yuan, and 47.92 million yuan respectively [2][3].

12月17日，奥精医疗大宗交易成交15万股，成交额288.87万元，占当日总成交额的3.21%，成交价19.26 元，较市场收盘价19.65元折价1.98%。 | No 224 080 Your 1 kill upo | | | | | | | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券商稼 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( *) 买入营业部 | | 卖出营业部 是否为专场 | | 025-12-17 | 奥精医疗 | 688613 | 19.26 288.87 ાર | 公詢证券劈致有限 | 190 發酵類 | ...

Core Viewpoint - The stock of Aojing Medical (688613) has shown a slight increase of 1.93% on December 15, 2025, closing at 20.02 yuan, with notable fluctuations in capital flow and financing activities [1][2]. Group 1: Stock Performance and Capital Flow - On December 15, 2025, Aojing Medical's stock closed at 20.02 yuan, with a trading volume of 40,400 hands and a total transaction amount of 80.583 million yuan [1]. - The capital flow data indicates a net inflow of 1.763 million yuan from main funds, accounting for 2.19% of the total transaction amount, while retail investors experienced a net outflow of 4.106 million yuan, representing 5.09% of the total [1][2]. - Over the past five days, the stock has experienced fluctuations in capital flow, with the highest net inflow from main funds recorded at 20.0116 million yuan on December 10, 2025 [2]. Group 2: Financing and Margin Trading - On December 15, 2025, the financing buy-in amounted to 12.8433 million yuan, with a net financing buy-in of 6.7929 million yuan, while the total financing balance reached 163 million yuan [3]. - The financing data over the past five days shows a trend of fluctuating net financing buy-ins, with a peak of 9.6018 million yuan on December 9, 2025 [3]. Group 3: Company Financial Performance - Aojing Medical reported a main revenue of 156 million yuan for the first three quarters of 2025, reflecting a year-on-year increase of 5.22%, with a net profit of 13.9406 million yuan, up 185.19% [5]. - The company's gross profit margin stands at 68.9%, significantly higher than the industry average of 51.02%, indicating strong operational efficiency [5]. - The company's total market capitalization is 2.743 billion yuan, with a net asset value of 1.449 billion yuan, positioning it below the industry average in several key financial metrics [5].